Gedea Biotech granted US patent for its antibiotic-free treatment pHyph for women with vaginal fungal infections
Lund, Sweden, August 31, 2021. Swedish women’s health company Gedea Biotech today announced that it has been granted a patent (US 10,993,907) by the United States Patent and Trademark Office (USPTO) for the treatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent can be kept in force until 2037.Recurring vaginal infections, including fungal infections affect at least 400 million women annually around the world and can be caused by either bacteria or fungi. Although bacterial vaginosis is the most common vaginal infection in women of reproductive age,